Abstract: Many advances in the treatment of squamous cell carcinoma of the head and neck have occurred in the past few years. Since the advent of cetuximab, a chimeric monoclonal antibody against epidermal growth factor receptor, the search for other efficacious targeted therapies has awakened the interest and curiosity of researchers and clinicians. Initially, cetuximab demonstrated effectiveness as single agent in heavily pretreated patients diagnosed with head and neck cancer, and has demonstrated to improve locoregional control and survival when combined with radiotherapy. The success of cetuximab has transitioned to other settings and with different modalities such as in combination with other conventional cytotoxic agents in the metastatic setting, combined with radiation therapy as part of concurrent treatment, and lately, in combination with other agents in the induction phase of the sequential approach. In this review, we discuss all different modalities in combination with cetuximab and how cetuximab has been incorporated into other clinical settings with only one goal in mind: improve the survival rates of our patients.
INTRODUCTION
Squamous cell carcinoma of the head and neck (SCCHN) represents 5% of all cancers and over 500,000 new cases are diagnosed yearly worldwide [1] . Approximately 49,260 new cases were diagnosed in the United States alone in 2010 [2, 3] . The overwhelming majority of head and neck cancers, over 90%, are squamous cell in origin [1] . Alcohol and tobacco use have been widely accepted as the most important risk factors, however, a newly recognized etiology is the presence of human papilloma virus (HPV) in these tumors [3] . The incidence of HPV positive cancers continues to rise both in total and as a proportion of all head and neck tumors. HPV positivity can be detected by either polymerase chain reaction (PCR) or by the presence of p16 immunohistochemistry (IHC) reactivity which demonstrates prior exposure to HPV in such tumors [4] . Several studies have shown that HPV positivity confers a good prognosis for SCCHN [5] . Nonetheless, all these reports are on the basis of retrospective studies. Its utility in terms of predicting response is unknown. The Radiation Therapy Oncology Group ongoing RTOG1016 study is designed to evaluate patients whose tumors are HPV positive. The impact of this novel biomarker in terms of prediction of response to therapy is a matter of ongoing research [6] .
Approximately two-thirds of patients present with advanced disease at diagnosis (stage III/IV), for which prognosis is poor [7] . Despite advances in the treatment of SCCHN, less than 30% of these cases will be cured and less than 50% will survive beyond 2 years [8] . Prognosis depends primarily on disease stage and performance status at the time of diagnosis [9, 10] . If the disease is left untreated, median survival is approximately 4 months [10] . Treatment of locoregional advanced disease is quite complex. Careful patient selection and staging are key elements of achieving success. Various combined therapeutic modalities have been used, including concurrent chemoradiation(chemotherapy and radiation administered in a simultaneous manner), induction chemotherapy followed by irradiation(neoadjuvant chemotherapy followed by definitive radiation), and sequential therapy (induction chemotherapy followed by concurrent chemoradiation). Concurrent chemoradiation confers and absolute survival benefit of 8% at 2-and 5 years [11, 12] . When induction chemotherapy or sequential therapy is used, the most common therapeutic regimen is TPF [13] .
The development of biological therapies has expanded the treatment options in this disease. Among targeted agents, the monoclonal antibody against the epidermal growth factor receptor (EGFR), cetuximab, stands as a major accomplishment and addition to the treatment for SCCHN. The correlation between EGFR and carcinogenesis has been well established for over 30 years ago with studies that identified an overexpression of EGFR in approximately 90-100% of SCCHN specimens [14] [15] [16] . EGFR expression in tumors is associated with more aggressive disease, increased resistance to chemotherapy and radiotherapy, increased metastasis, poor prognosis, and decreased survival [17] [18] [19] . Cetuximab is approved in the United States for the treatment of refractory/metastatic SCCHN as a single agent, in combination with conventional chemotherapy as well, and in combination with radiation therapy for patients with locally advanced (LA)-SCCHN. Due to its efficacy and tolerability, several efforts have been made to move this agent to other therapeutic approaches (as part of sequential or induction regimens) as well as novel combined regimens. In this comprehensive review, the authors discuss the addition of cetuximab into the induction phase of the complex management of patients with LA-SCCHN.
THE

PLATFORM FOR INDUCTION CHEMOTHERAPY IN SCCHN
Induction chemotherapy has many theoretical advantages (i) reduction in tumor size which facilitates local therapy with surgery or radiation, (ii) treatment of micrometastatic disease, (iii) optimal delivery of chemotherapeutic drugs via undisrupted tumor vasculature, (iv) an opportunity to evaluate the biological activity of novel therapeutic agents, and (v) assess for potential predictive biomarkers. Moreover, induction chemotherapy offers the opportunity of assessing tumor response in vivo and thereby facilitating patient selection for subsequent organpreserving interventions . We have witnessed this strategy being used, as organ-preserving therapy, for the larynx and hypopharynx [20] [21] [22] [23] [24] [25] . These landmark studies have demonstrated that laryngeal preservation can be achieved in up to two-thirds of patients with stage III/IV laryngeal cancer without compromising overall survival (OS), when using induction chemotherapy followed by radiation. In addition, there is a decrease in the rate of distant metastatic recurrence in the patients treated with induction chemotherapy followed by radiation over the patients who underwent surgery followed by radiation. Interestingly, concurrent chemoradiotherapy has shown to be superior than induction chemotherapy followed by radiation and to radiation alone in the RTOG91-11 trial [21] . in the PF group, completed the chemotherapy as defined by protocol. Dose delays were more common in the PF group. Grade 3/4 neutropenia and leucopenia were more common in the TPF group, and severe thrombocytopenia and anemia were more common in the PF group. Deaths associated with toxic effects occurred in 4 patients in the TPF group (2.3%) and in 10 patients in the PF group (5.5%). Patients in the TPF group had a reduction of 27% in the risk of death, an improvement in median OS of 4.3 months, and an absolute increase in 3-year survival of 10.9% [26] . The second study, TAX 324, compared three cycles of TPF vs three cycles of PF; induction chemotherapy followed by 7 weeks of concurrent chemoradiotherapy (the sequential approach). The TPF regimen consisted of docetaxel 75 mg/m 2 , cisplatin 100 mg/m 2 , both at day 1, and fluorouracil 1000 mg/m 2 /day by continuous infusion for 4 days. The PF regimen consisted of cisplatin at a dose of 100mg/m2 and fluorouracil 1000mg/m2 continuous infusion for 5 days. Herein, concurrent chemoradiation was given within 3 to 8 weeks after the start of the third cycle of induction chemotherapy. Weekly carboplatin at an area under the curve (AUC) of 1.5 was administered for a maximum of seven doses. Radiation therapy consisted of 2 Gy/day, 5 days/week; for a total of 70 Gy. A total of 501 patients underwent randomization; 255 and 246 patients were assigned to the TPF and PF groups, respectively. At a median follow-up of 42 months, treatment with TPF resulted in a 30% reduction in the risk of death. Median survival was 71 months in the TPF group and 30 months in the PF group. Estimated 3-year survival was 62% in the TPF group and 48% in the PF group. As compared with the PF group, the TPF group had a significant reduction in the risk of disease progression or death. The median progression-free survival (PFS) was 36 months in the TPF group, and 13 months in the PF group. The overall response rate (ORR) after induction chemotherapy was 72% in the TPF group and 64% in the PF group. Grade 3 or 4 thrombocytopenia was more frequent in the PF group than in the TPF group (11% vs. 4%). Patients in the TPF group had fewer treatment delays than did those in the PF group (29% vs. 65%). No significant differences in the rates of adverse events were observed during chemoradiation [27] .
These two studies established a novel regimen for induction therapy by adding docetaxel, a microtubule inhibitor, to the standard Cisplatn/Fluorouracil regimen. . Most notably, these studies also proved the feasibility of delivering a triplet cytotoxic chemotherapy regimen without decreasing the number of patients that will proceed to definitive radiation therapy.
Despite the tremendous objective response, tolerability, and outcomes found with induction TPF followed by definitive radiation therapy or concurrent chemoradiation, we have not been able to define the best therapeutic approach for LA-SCCHN. What is superior: induction chemotherapy followed by definitive radiation, induction chemotherapy followed by concurrent chemoradiation, or induction chemotherapy followed by surgery and then concurrent chemoradiation? Thus far, only one randomized phase III study comparing both modalities of treatment has been completed. In this study, 382 patients with LA-SCCHN were randomized and treated with induction chemotherapy followed by concurrent chemoradiation or surgery. Induction chemotherapy had two arms: arm A received cisplatin 100 mg/m 2 [13] .
THE EFFECTIVENESS OF CHEMOIMMUNO-THERAPY IN SCCHN
Cetuximab is a recombinant chimeric monoclonal antibody that binds to the extracellular ligand-binding domain of the EGFR and also the mutant receptor EGFRvIII, inducing internalization and downregulation of the EGFR [28, 29] . This binding blocks the activation of the EGFR pathway, providing many antitumor effects such as induction of apoptosis, cell-cycle arrest at the G0/G1 boundary, inhibition of angiogenesis, decrease in metastasis, and enhancement of the sensitivity to radiotherapy [17, 30, 31] . Cetuximab is administered intravenously at a recommended loading dose of 400 mg/m 2 on day one followed by a weekly dose of 250 mg/m 2 [32] [33] [34] . The most serious side effects are dermatologic toxicity, infusion reactions and pulmonary toxicity [32] .
The integration of cetuximab to radiation has had a significant impact in patients with locoregional advanced stage III/IV SCCHN [30, 31] . The addition of cetuximab to radiation provides an absolute OS benefit of 9% at 5 years [31] . Given these encouraging results as well as safety and tolerability of cetuximab, further studies evaluated this agent in combination with chemotherapy as first line treatment for recurrent or metastatic patients. Baselga et al. conducted a phase II study comparing the addition of cetuximab to platinumbased chemotherapy in platinum-refractory metastatic or recurrent SCCHN. All patients received a minimum of two and a maximum of four cycles of platinum-based chemotherapy alone or in combination with other agents before study entry. Ninety-six patients were enrolled to receive cetuximab 400 mg/m 2 loading dose on day one, with subsequent weekly doses of 250 mg/m 2 followed by cisplatin 60 mg/m 2 or carboplatin 250 mg/m 2 . For most of the patients (78%), the relative dose intensity (RDI) of cetuximab was > 90%. Less than 15% of patients experienced grade 3 or 4 toxicity, with acne-like skin reactions being the most common adverse effect. No cetuximab related-deaths were reported. ORR was 10%, with the median response lasting more than 5 months, and an OS of 183 days. In this study, the addition of cetuximab demonstrated good clinical activity with tolerable safety profile [36] . In a phase III study by Burtness et al., 117 patients were randomized to receive either cetuximab plus cisplatin or cisplatin alone as first-line treatment in patients with metastatic or recurrent SCCHN. The patients received cetuximab 400 mg/m 2 on day one followed by weekly doses of 250 mg/m 2 plus cisplatin 100 mg/m 2 every 4 weeks or single-agent cisplatin 100 mg/m 2 every 4
weeks. The combination of cetuximab plus cisplatin demonstrated a higher ORR of 26% compared to 10% for cisplatin alone. However, OS and PFS were not statistically significant. The most common adverse reactions were neutropenia and skin toxicity, with no deaths related to cetuximab [37] . Another study conducted by Herbst et al. confirmed the superiority in terms of response rate when cetuximab was added to conventional platinum-based chemotherapy in resistant recurrent or metastatic SCCHN patients [38] . This study evaluated cetuximab plus cisplatin in patients with stable disease (SD) and progressive disease (PD1) after two 3-week cycles on cisplatin plus paclitaxel or cisplatin plus fluorouracil. Those patients who did not progress after two 3-week cycles continued their current therapy until progression of disease (PD2) and at that time they started cetuximab therapy. Cetuximab was administered at a loading dose of 400 mg/m 2 followed by weekly doses of 250 mg/m 2 plus cisplatin 75 or 100 mg/m 2 on day one every 3 weeks.
The ORR was 18% for the SD group, 20% and 6% for the PD1 and PD2 group. The median duration of response was 4.2, 4.1, and 7.4 months for the PD1, PD2, and SD groups, respectively. Noteworthy, median OS for the SD patients was 11.7 months [38] .
One of the most striking results using this monoclonal antibody in combination with chemotherapy was found in the cetuximab (ErbituX) in combination with cisplatin or carboplatin and 5-fluorouracil in the first line Treatment of subjects with REcurrent and/or MEtastatic SCCHN (EXTREME) trial. This landmark study was the first randomized, placebo-controlled study to demonstrate a survival benefit in adding cetuximab to first line chemotherapy for recurrent or metastatic SCCHN patients. This study randomized 442 patients to receive either cisplatin or carboplatin plus 5-flurouracil alone or in combination with cetuximab. All patients had confirmed recurrent or metastatic SCCHN and a Karnofsky performance score of 70 or more. The regimen consisted in cisplatin 100 mg/m 2 or carboplatin at AUC 5 as a one-hour intravenous infusion on day 1 and 5-fluorouracil 1000 mg/m 2 for 4 days by continuous infusion every 3
weeks. Cetuximab was given at its standard loading and weekly dosing. Patients received a maximum of six cycles of chemotherapy, and those in the cetuximab group who had at least SD received cetuximab monotherapy until disease progression or unacceptable toxic effects. Patients in both groups received similar number of chemotherapy cycles and over 83% of the patients had a RDI of 80% or more for each therapy agent. The frequency of toxicity events did not differ between the two groups. The OS was 10.1 months for patients treated with cetuximab plus chemotherapy and 7.4 months for chemotherapy alone. Therefore, an extension of 2.7 months in the median OS and a 20% reduction in the relative risk of death was associated with the addition of cetuximab to standard chemotherapy. [39] . Furthermore, a subset analysis of the EXTREME trial assessed the impact of treatment on the quality of life of the patients. The results showed that adding cetuximab to platinum-fluorouracil regimen does not negatively affect the quality of life of patients with recurrent or metastatic SCCHN [40] . A retrospective analysis has also evaluated the influence of EGFR gene copy number, determined by FISH, on clinical outcome in the EXTREME trial. There was no association between FISH score and OS, PFS, or best overall response. Patients with FISH positive tumors were evenly distributed between the chemotherapy plus cetuximab (50/158) and the chemotherapy alone (51/154) arms. With this data, we can conclude that EGFR gene copy number, as determined by FISH, is not a predictive biomarker for cetuximab efficacy in recurrent or metastatic SCCHN [41] .
Substantial evidence supports the efficacy of cetuximab in combination with standard cytotoxic chemotherapy in recurrent and/or metastatic disease.
But, is it advantageous to add cetuximab to standard induction chemotherapy?
ADDING
CETUXIMAB INTO INDUCTION CHEMOTHERAPY STRATEGIES
As a Single Approach in Induction Therapy
Cetuximab has been used as a single agent induction therapy followed by concurrent chemoradiation therapy. This has been evaluated in a phase II study that enrolled 29 patients. All the patients received induction cetuximab at its standard loading and weekly dosing for 4 weeks [42] . Potentially operable patients then received cetuximab 250 mg/m 2 , paclitaxel 40 mg/m 2 , and carboplatin at AUC =1 weekly for 5 weeks plus radiation 45Gy. Patients subsequently underwent endoscopic biopsy. If biopsy proven to be negative, the patients were further treated with 3 additional weekly doses of cetuximab, paclitaxel, and carboplatin plus radiation 22-27 Gy. Inoperable patients received 8 weeks of cetuximab, paclitaxel, and carboplatin plus radiation 66.6-72 Gy. All patients then received maintenance cetuximab 250 mg/m 2 weekly for 24 weeks. Responses to induction cetuximab using the RECIST criteria were 14 (61%) patients with SD, 7 (30%) had a PR, and 1 (4%) had a CR [42] .
A Triplet Approach as Induction Therapy
Kies et al. treated 47 patients with paclitaxel, carboplatin, and cetuximab induction chemotherapy. All patients had previously untreated stage IVA/B SCCHN. On week one, the patients received a combination of paclitaxel 135 mg/m 2 , carboplatin at AUC=2, and cetuximab 400 mg/m 2 loading dose followed by paclitaxel 135 mg/m 2 , carboplatin AUC=2, and cetuximab 250 mg/m 2 weekly for up to 6 weeks.
Induction chemotherapy was followed by either surgery (n=1), radiation (n=23) or concurrent chemoradiation (n=23). Radiation or concurrent chemoradiation was started 2 to 3 weeks after completion of the induction chemotherapy phase. The patients received a total radiation dose of 66-72 Gy with concurrent cisplatin 100 mg/m 2 on days 1 and 22, for a total of 6 weeks. OS at 3 years was 91% with a PFS of 87%. Distant metastases were observed in 4 of 47 patients. Functional outcomes were encouraging, with a 3% gastrostomy tube dependence and 8% aspiration rate [43] . [46] .
A Quadruplet Approach as Induction Therapy
A phase I study which was designed to determine the maximum tolerated dose (MTD) of 5-fluorouracil, in the TPF regimen, plus cetuximab induction chemotherapy followed by concurrent chemoradiation in LA-SCCHN patients reported a safe toxicity profile as a preliminary result [47] . The dose escalation scheme of 5- (3) . In general, the regimen had an acceptable toxicity profile [48, 49] .
A retrospective study analyzed the efficacy and tolerability in 23 patients who received cetuximab, docetaxel, cisplatin and 5-fluorouracil as induction chemotherapy for LA-SCCHN [50] . /day infusion for 3 days being given every 3 weeks. This study showed a tumor response rate at the primary site of 71% as well as no grade 3/4 toxicity.
CONCLUSIONS
LA-SCCHN is a disease that truly posses a challenge towards physicians. With perhaps a small window of opportunity for cure, clinicians face the difficult decision of providing the best treatment option tailored towards those patients. The two options that head and neck multidisciplinary group faces are: immediate and definitive concurrent chemoradiation versus induction chemotherapy followed by definitive concurrent chemoradiation (sequential approach). Effective management of patients with advanced SCCHN consists of a true multidisciplinary approach involving medical oncologists, head and neck surgeons, radiation therapists, speech therapists, nutritionists, pain service, and social workers.
Over the past two decades, we have witnessed the pendulum for and against induction chemotherapy sway several times for the management of SCCHN. Now, with the emergence of novel targeted agents such as cetuximab and the addition of taxanes to cisplatin/5-fluorouracil-based regimen, the door has been opened to revisit the idea of induction "chemoimmunotherapy" for SCCHN. Cetuximab has demonstrated, although in small studies, to be a safe and an effective agent in combination with chemotherapy for SCCHN in the induction phase. Superior response rates including CR were achieved with cetuximab plus induction chemotherapy than those reported in large randomized controlled trials, 68-72%, using TPF induction chemotherapy [27, 28] . Certainly, we need to define the best combination (agents and dosing schedule) to be paired with cetuximab: a triplet or quadruplet. Then, a large randomized phase III trial, with strict and rigorous eligibility criteria and trial design, will be required to finally answer the questions: Is induction therapy followed by concurrent chemoradiation superior than chemoradiation alone?, and Is there a subset of these patients who may have a greater benefit from this approach?
There is no question that targeted agents are offering the chance to attack malignant cells from different pathways, adding efficacy to the already established regimens and with better toxicity profile. Thus, it is in our hands to exploit this opportunity and change the dismal outcomes that we have seen in LA-SCCHN.
